ORIC Pharmaceuticals plans Phase 3 enozertinib trial in lung cancer for first half of 2027
Bitget2026/10/23 07:15- ORIC Pharmaceuticals plans to start Redwood-1, a global Phase 3 trial of enozertinib in first-line EGFR atypical lung cancer, in first-half 2027.
- Phase 1b results presented at ESMO Congress 2026 showed tumor shrinkage, including brain metastases, with some brain tumors disappearing completely.
- Treatment-related side effects caused no discontinuations; survival and response-duration findings remain immature.
- The planned trial will enroll approximately 360 patients, comparing enozertinib with physician-selected osimertinib or afatinib.
- Response results could support accelerated approval, while progression-free survival will underpin the full-approval assessment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
